ArticleFrontiers in medicine2025
Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploratory Mediation-Informed Analysis and Dose-Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol.Medical sciences (Basel, Switzerland) · 2026Article
- Gouty kidney disease: a tubulointerstitial paradigm reimagined-early detection, precision stratification, and targeted intervention.Rheumatology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effectiveness of sodium-glucose cotransporter type 2 (SGLT2) inhibitors combined with traditional urate-lowering therapy (ULT) in people with gout, we conducted a retrospective, single-center observational study in a crystal arthritis clinic. Primary outcomes were reduction in serum urate (SU) levels and achievement of SU targets (<6 mg/dL and <5 mg/dL). We also compared prescribed allopurinol doses versus Easy-Allo-predicted doses and evaluated changes in diuretic use. The sample comprised 46 individuals (median age 75 years; 82.6% men) with a high prevalence of long-standing gout and comorbidities. Combined treatment was associated with a median SU reduction of 0.85 mg/dL (95% CI -1.7 to -0.1,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.